🔗 Share this article

While the US undertakes sweeping changes to its immunization guidelines, an unexpected name appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has zeroed in on alleged fatalities after Covid immunization in her short position at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Schedule

Agency leaders had intended to unveil sweeping changes to the childhood immunization program in December, aligning the US with the Danish national calendar, according to reports – a major change that would place the US out of step with a large portion of the international standard with insufficient data for benefit. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the center this calendar year.

A New Direction at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Prasad solidify control at the FDA – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for halting certain pediatric vaccine recommendations in the US so as to align more similar to Denmark, a nation with nationalized medicine and a citizenry about the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Background

The appointee has little discernible experience in pharmaceutical research, oversight or administrative roles, which has been customary for former directors of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in managing a large organization. She has no expertise in industry regulation.”

Past directors of CBER would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that previous people who headed CBER have had.”

CDER has an immense range of responsibilities at the FDA, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the generic drug division clears thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and other areas, and all of those need to be supervised,” she noted. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the role, which supervises over 5,000 staff members. “It is a huge leadership role, if you execute it properly,” she added.

Response and Disputed Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment signifies greater collaboration among FDA leaders on immunizations, a press secretary said that the “questions stem from inaccurate presumptions”.

“Her experience aligns with the functions of her role,” the representative stated, noting the period Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the commissioner’s new fast-track approval initiative, a disputed one-day medication authorization process that reportedly troubled her preceding directors. “By what process are these drugs being chosen for this voucher program? Who makes the choices?” Howard said. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of pharmaceuticals, with the exception of immunizations.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if concerning, history, some experts said. She released a analysis using unverified public submissions to determine the frequency of heart inflammation following Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are riskier than they are.

Part of her “policy goals” for the incoming federal leadership featured revising guidelines for recently developed shots and ending “non-essential” immunizations, she said following the vote on a online show. At the FDA, Dr. Høeg has reportedly suggested barring teenage boys from receiving Covid vaccinations.

“She is an all-around dogmatist who commences with her conclusions and works backwards to fit the evidence in a very disingenuous, fraudulent fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow skeptics, {like|